Pfizer secures US$10.5B Innovent Biologics alliance to scale its oncology pipeline

USA—Pfizer and Innovent Biologics have entered into a landmark global licensing and collaboration agreement, valued at up to US$10.5 billion, to accelerate research and development of a portfolio of 12 promising early-stage cancer medicines.

The partnership marks one of the largest oncology-focused collaborations announced this year and highlights the growing importance of international alliances in advancing innovative cancer therapies.

The agreement brings together Pfizer’s global expertise in clinical development, regulatory affairs, and commercialization with Innovent’s strengths in scientific discovery and early-stage oncology research.

Through the collaboration, the companies aim to speed up the development of novel cancer treatments while expanding access to potentially transformative therapies for patients worldwide.

Focus on novel cancer technologies

The collaboration covers a diverse portfolio that includes antibody-drug conjugates (ADCs) featuring innovative payload technologies as well as multi-specific antibodies designed to engage the immune system through distinct mechanisms.

These advanced therapeutic approaches have attracted significant interest across the pharmaceutical industry because of their potential to improve treatment precision and enhance anti-tumour activity.

Of the 12 programmes included in the agreement, eight originate from Innovent’s existing oncology pipeline, while four are discovery-stage programmes proposed by Pfizer.

The companies will jointly develop selected candidates and share development costs as the medicines progress through clinical testing.

Under the arrangement, Innovent will lead research activities and early clinical development through Phase I trials, leveraging its proprietary drug discovery platform and oncology expertise.

Once the programmes move beyond this stage, Pfizer will take responsibility for global development efforts, drawing on its extensive international clinical and regulatory infrastructure.

Structure of the collaboration

The agreement divides the portfolio into three categories, each with a distinct commercial framework.

For four of the medicines, Pfizer will receive exclusive worldwide rights and will assume full responsibility for global development and commercialization costs.

Another four programmes will grant Pfizer exclusive rights outside Greater China, while Innovent retains regional rights and Pfizer covers most development expenses.

The remaining four programmes will be jointly developed worldwide.

Under this arrangement, both companies will share development costs, co-commercialize approved products in the United States and Europe, and split profits generated in those markets.

Innovent will retain commercial rights in Greater China for these assets.

Financial terms and growth opportunities

As part of the transaction, Innovent will receive an upfront payment of US$650 million.

In addition, the company could earn up to US$9.85 billion in development, regulatory, and commercial milestone payments if the programmes successfully advance through clinical development and achieve regulatory approvals.

Innovent will also be eligible to receive double-digit royalties on sales of licensed products.

Furthermore, profit-sharing arrangements will apply to the co-developed and co-commercialized medicines marketed in the United States and Europe.

Industry analysts view the deal as another indication of growing interest among multinational pharmaceutical companies in China’s rapidly expanding biotechnology sector.

Recent data show that licensing agreements involving Chinese biotech firms have increased sharply over the past few years as global drugmakers seek access to innovative research programmes and emerging technologies.

Executives highlight shared vision

Commenting on the partnership, Pfizer Chief Oncology Officer Jeff Legos said the company remains focused on improving outcomes for people living with cancer and advancing medicines that can change standards of care.

According to Legos, the collaboration combines two highly complementary innovation engines with a shared goal of accelerating the development of breakthrough therapies.

He noted that integrating Innovent’s discovery and early clinical development capabilities with Pfizer’s global research, development, and commercialization network could strengthen the oncology pipeline while bringing innovative treatments to patients more quickly.

Innovent’s Chief R&D Officer for Oncology Pipeline, Dr. Hui Zhou, said the agreement would enable both organizations to leverage their complementary strengths to advance novel cancer medicines on a global scale.

He added that co-developing and co-commercialising selected programmes in the United States and Europe would further expand Innovent’s international presence and support its ambition of building a globally recognised oncology platform.

Recent developments at Pfizer

The announcement comes amid a period of significant activity within Pfizer’s research and development portfolio.

In recent weeks, the company reported encouraging long-term results from its CROWN trial evaluating LORBRENA for advanced non-small cell lung cancer, with data showing what Pfizer described as the longest progression-free survival reported to date in this patient population.

Pfizer has also continued to expand its hematology portfolio.

In May, the European Commission approved an expanded indication for Hympavzi (marstacimab), allowing its use in adults and adolescents aged 12 years and older with haemophilia A or B who have inhibitors.

The approval broadened treatment options for patients living with these rare bleeding disorders across the European Union.

The Pfizer–Innovent transaction is expected to close during the third quarter of 2026, subject to customary regulatory approvals and other closing conditions.